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ABSTRACT 
Cancer has a significant impact on the Australian community. One in three men and one in four women will 
develop cancer by the age of 75. The estimated annual health expenditure due to cancer in 2000 1 in Australia was 
$2.7 billion, representing 5.5% of the country’s total healthcare expenditure. An historical overview of the national 
cancer  control  strategies  in  Australia  is  provided.  In  males,  the  five  most  common  cancers  in  order  of  decreasing 
incidence are: prostate cancer, colorectal cancer, lung cancer, melanoma and lymphoma, while for Australian women, 
breast  cancer  is  the  most  common  cancer.  Key  epidemiologic  information  about  these  common  cancers,  current 
management issues and comprehensive national clinical practice guidelines (where available) are highlighted. Aspects of 
skin  cancer,  a  particularly  common  cancer  in  the  Australian  environment  –  with  a  focus  on  melanoma  –  are  also 
included. 
Cancer outcomes in Australia, measured by selected outcomes, are among the best in the world. However, there is 
still evidence of health inequalities, especially among patients residing in regional and remote areas, the indigenous 
population and people from lower socio economic classes. Limitations of current cancer care practices in Australia, 
including provision of oncology services, resources and other access issues, as well as suggested improvements for 
future cancer care, are summarised. Ongoing implementation of national and state cancer control plans and evaluation of 
their effectiveness will be needed to pursue the goal of optimal cancer care in Australia. © 2008 Biomedical Imaging 
and Intervention Journal. All rights reserved. 
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OVERVIEW OF CANCERS AND CANCER STATISTICS IN 
AUSTRALIA 
Cancer  has  a  significant  impact  on  the  Australian 
community. One in three men and one in four women 
will develop cancer by the age of 75. In 2004, there were 
over  98,000  new  cases  of  cancer  (excluding  non 
melanomatous  skin  cancer  [NMSC])  and  over  36,000 
deaths attributable to cancer in Australia, in a population 
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of just over 20 million people. This represented a 4.7% 
increase  from  cases  diagnosed  in  2003  and  a  25.2% 
increase from 1994 [1]. Both the number of new cases is 
increasing,  as  is  the  number  of  people  living  with the 
diagnosis of cancer [2]. Between 1990 and 2000, there 
was a 36% increase in new cancer cases, but only a 12% 
population  growth.  The  annual  age standardised 
incidence rate is 338 per 100,000 people, with a 1 in 3 
risk of developing a cancer before the age of 75 and 1 in 
2 by the age of 85 [1].  
Cancer is the leading cause of death and the leading 
cause  of  loss  of  Disability  Adjusted  Life  Years.  Over 
60% of people diagnosed with cancer survive more than 
five years in Australia, a figure that is second only to the 
USA. It is estimated that over 247,000 people are living 
in the Australian community with a cancer diagnosis up 
to  five  years  earlier  (excluding  NMSC)  [1,3].  The 
estimated  annual  health  expenditure  due  to  cancer  in 
2000 1  in  Australia  was  $2.7  billion  [4],  representing 
5.5% of the total healthcare expenditure.  
CANCER CONTROL AND HEALTHCARE POLICY IN 
AUSTRALIA  
Australia  has  a  complex  healthcare  system.  The 
Australian  (Federal)  Government  subsidises  out of 
hospital medical services through its Medicare system [5] 
created  as  a  universal  access  healthcare  system  for 
Australian  citizens.  The  Federal  Government  also  has 
responsibility for the breast and cervical cancer screening 
programs, the Pharmaceutical Benefits Scheme (PBS) [6], 
and  other  areas  of  service  provision  including 
radiotherapy services and aged care. Hospital care and 
some community services are the responsibility of State 
and Territory governments and these are publicly funded, 
with private services supported by health insurance plans. 
Cancer care and cancer control have a large component 
of  non government  and  non profit  (voluntary)  support, 
the  latter  notably  including  Cancer  Councils,  based  in 
each State and Territory with a national office, and The 
Cancer Council Australia.  
NATIONAL CANCER CONTROL STRATEGIES IN 
AUSTRALIA – A HISTORICAL OVERVIEW  
In  1994  the  publication  ‘Better  Health  for 
Australians’  [7]  was  released.  Cancer  was  one  of  the 
initial  health  focus  areas  selected  in  recognition  of  its 
effects on the Australian population and the potential to 
reduce  morbidity  and  improve  quality  of  life  by 
improving  cancer  control.  Seven  priority  cancers  were 
selected:  breast,  cervical,  lung,  colorectal,  melanoma, 
non melanomatous skin cancer and prostate cancer. The 
Australian  Cancer  Society  (now  the  Cancer  Council 
Australia)  conducted  a  national  series  of  expert 
workshops and from this produced the ‘National Cancer 
Prevention  Policy  for  Australia’  [8 10].  Prevention 
strategies  covered  tobacco,  ultraviolet  (UV)  radiation, 
diet,  physical  activity,  overweight  and  obesity,  and 
alcohol related issues. This policy [9] also included goals 
and strategies related to screening for breast, cervical and 
colorectal  cancer.  Consensus based  proposed  actions 
were developed subsequently and published in ‘Cancer 
Control towards 2002’ [9,11]. 
In  2003,  the  Optimising  Cancer  Care  in  Australia 
(OCCA) report [2] compiled with key organisations and 
individuals in the field of cancer care, aimed to identify 
systematic problems, barriers and failings of the current 
system  of  cancer  care  in  Australia.  The  OCCA  report 
helped  stimulate  major  action  in  cancer  control  in 
Australia at both national and state levels, and is one of 
the  key  documents  on  which  the  National  Service 
Improvement  Framework  (NSIF)  for  Cancer  [2,12]  is 
based. The eight priority actions include establishing: 
●  Integrated and networked cancer services; 
●  Accreditation  for  cancer  services  and 
credentialing of practitioners; 
●  Funding structures to support multi disciplinary 
care; 
●  Approaches to monitor cancer control; 
●  Provision  of  consumer  information  about 
cancer  risks,  prevention,  early  detection, 
diagnosis and treatment, and supportive care; 
●  Support for primary care providers to provide 
appropriate assessment of risk; 
●  Implementation  and  evaluation  of  culturally 
appropriate programs to improve cancer control; 
and 
●  Review of gaps in research and opportunities at 
least every three years. 
The strengths, weaknesses and future directions of 
these initiatives will be discussed in a later section.  
Common cancers in Australia 
In males, the five most common cancers in order of 
decreasing incidence are: 
1.  Prostate cancer  
2.  Colorectal cancer  
3.  Lung cancer  
4.  Melanoma 
5.  Lymphoma  
Tables 1 and 2 outline the incidence and mortality 
figures for the five most common cancers in Australian 
males over the period 1996 2004 [1].  
In females, the five most common cancers in order 
of decreasing incidence are: 
1.  Breast cancer  
2.  Colorectal cancer  
3.  Melanoma 
4.  Lung cancer 
5.  Lymphoma  
Tables 3 and 4 outline the incidence and mortality 
figures for the five most common cancers in Australian 
females over the period 1996 2004 [1].  
The  following  section  summarises  some  key 
epidemiologic information about these common cancers 
in  Australia  and  highlights  current  issues  and 
methodologies  in  management.  Where  available  for 
2 ES Koh et al. Biomed Imaging Interv J 2008; 4(3):e30     
    This page number is not 
    for citation purposes 
 
 
 
 
 
Table 1  The five most common cancers in Australian males over the period 1996 2004 [4] (Rates are age 
standardised to the Australian population and expressed per 100,000 population). 
Cancer site/type   1996  1997  1998  1999  2000  2001  2002  2003  2004 
Prostate   137.6  129.8  128.1  129.5  128.2  130.3  134.4  146.8  163.4 
Colorectal   78.3  77.2  74.8  75.2  79.6  78.4  75.7  73.8  75.1 
Lung, bronchus & trachea   69.8  69.3  67.5  65.6  63.4  62.1  60.7  58.6  61.6 
Melanoma of skin   53.8  56.0  52.3  54.2  54.7  55.5  59.9  58.1  56.6 
Lymphoma   23.9  23.4  22.9  23.6  24.1  23.8  24.6  24.4  24.3 
All cancers   563.0  553.2  544.0  545.4  544.8  548.7  553.6  556.7  573.4 
Notes: 
(a)  Non melanoma skin cancer (NMSC, ICD 10 code C44), known to be the most common cancer type, is excluded from 
this list because basal cell carcinoma and squamous cell carcinoma, the two most common types of NMSC, are not 
notifiable cancers. 
(b)  Rates are age standardised to the Australian population at 30 June 2001 and expressed per 100,000 population. 
(c)  Source of data: National Cancer Statistics Clearing House, AIHW. 
 
 
 
 
 
 
 
Table 2  Mortality figures from 2004 for Australian males for the five most common cancers (Rates are age 
standardised to the Australian population and expressed per 100,000 population) [4] 
  New cases    Deaths 
Cancer site/type  Number  % of total  Rate  Risk    Number  % of total  Rate  PYLL 
Prostate  15,759  28.7  163.4  1 in 5    2,792  12.9  33.0  6,193 
Colorectal   7,160  13.0  75.1  1 in 10    2,196  10.1  23.8  14,483 
Lung, bronchus & trachea  5,826  10.6  61.6  1 in 11    4,733  21.8  50.8  28,190 
Melanoma of skin  5,503  10.0  56.6  1 in 15    815  3.8  8.7  8,605 
Lymphoma   2,352  4.3  24.3  1 in 33    803  3.7  8.8  6,513 
All cancers   54,870  100.0  573.4  1 in 2    21,670  100.0  237.5  295,080 
Notes: 
(a)  Non melanoma skin cancer (NMSC, ICD 10 code C44), known to be the most common cancer type, is excluded from 
this list because basal cell carcinoma and squamous cell carcinoma, the two most common types of NMSC, are not 
notifiable cancers. However, NMSC is included in the data in the mortality columns. In 2004 there were a total of 360 
(including 251 male deaths) from NMSC. 
(b)  Rates are age standardised to the Australian population at 30 June 2001 and expressed per 100,000 population. 
(c)  Risk in 2004 of being diagnosed with a particular cancer before reaching age 85 years. 
(d)  Potential years of life lost (PYLL) between the ages of 0 and 84 years. 
(e)  Sources of data: National Cancer Statistics Clearing House and National Mortality Database, AIHW. 
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Table 3  The  five  most  common  cancers  in  Australian  females  over  the  period  1996 2004.  (Rates  are  age 
standardised to the Australian population and expressed per 100,000 population) [4] 
Cancer site/type   1996  1997  1998  1999  2000  2001  2002  2003  2004 
Breast   109.1  111.4  114.6  111.2  115.6  117.2  117.2  112.2  112.8 
Colorectal   52.3  52.5  52.0  53.8  52.7  54.5  51.8  51.5  51.5 
Melanoma of skin   38.1  40.3  37.1  37.6  38.4  38.4  40.8  38.0  39.4 
Lung, bronchus & trachea   26.4  27.0  26.3  26.2  27.9  28.0  28.9  27.7  29.3 
Lymphoma   16.9  17.4  17.1  17.2  17.7  17.0  17.9  17.1  17.5 
All cancers   385.9  390.2  392.0  388.0  394.5  396.8  402.7  389.9  395.4 
Notes: 
(a)  Non melanoma skin cancer (NMSC, ICD 10 code C44), known to be the most common cancer type, is excluded from 
this list because basal cell carcinoma and squamous cell carcinoma, the two most common types of NMSC, are not 
notifiable cancers. 
(b)  Rates are age standardised to the Australian population at 30 June 2001 and expressed per 100,000 population. 
(c)  Source of data: National Cancer Statistics Clearing House, AIHW. 
 
 
 
 
 
 
 
Table 4  Mortality figures from 2004 for Australian females for the five most common cancers. (Rates are age 
standardised to the Australian population and expressed per 100,000 population) [4] 
  New cases    Deaths 
Cancer site/type  Number  % of total  Rate  Risk    Number  % of total  Rate  PYLL 
Breast   12,126  27.9  112.8  1 in 9    2,664  15.8  23.8  48,910 
Colorectal   5,817  13.4  51.5  1 in 14    1,872  11.1  16.0  21,798 
Melanoma of skin   4,219  9.7  39.4  1 in 24    385  2.3  3.4  6,790 
Lung, bronchus & trachea   3,270  7.5  29.3  1 in 24    2,526  15.0  22.3  34,770 
Lymphoma   1,920  4.4  17.5  1 in 46    736  4.4  6.3  8,725 
All cancers   43,466  100.0  395.4  1 in 3    16,819  100.0  145.8  229,483 
Notes: 
(a)  Non melanoma skin cancer (NMSC, ICD 10 code C44), known to be the most common cancer type, is excluded from 
this list because basal cell carcinoma and squamous cell carcinoma, the two most common types of NMSC, are not 
notifiable cancers. However, NMSC is included in the data in the mortality columns. In 2004 there were a total of 360 
(including 109 female deaths) from NMSC. 
(b)  Rates are age standardised to the Australian population at 30 June 2001 and expressed per 100,000 population 
(c)  Risk in 2004 of being diagnosed with a particular cancer before reaching age 85 years. 
(d)  Potential years of life lost (PYLL) between the ages of 0 and 84 years. 
(e)  Sources of data: National Cancer Statistics Clearing House and National Mortality Database, AIHW. 
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relevant cancers, national clinical practice guidelines are 
referenced.  
SKIN CANCER – A COMMON CANCER IN THE 
AUSTRALIAN ENVIRONMENT  
Melanoma and non-melanomatous skin cancer 
The ultraviolet (UV) light in sunlight damages the 
DNA in skin, causing skin cells to mutate and contribute 
to the process of carcinogenesis. Humans have evolved a 
protective  mechanism  for  filtering  out  UV  light  from 
specialised  skin  cells  (melanocytes),  which  produce  a 
dark pigment called melanin that absorbs UV light and 
prevents  its  damaging  effects  [13,  14].  The  mass 
migration  of  peoples  in  the  19th and  20th centuries 
redistributed populations with low melanin protection to 
high UV regions. For example, when fair skinned Anglo 
Celtics and Europeans migrated to hotter climates such 
as that in Australia, the rates of skin cancer increased 
[14]. Australians have the highest documented incidence 
of skin cancer in the world, and skin cancer is the most 
common form of cancer in Australia, where the lifetime 
risk of skin cancer is 1 in 2 people [1]. Those persons 
most at risk are: 
●  Persons with fair skin and blue eyes (having the 
least amount of melanin)  
●  Persons with significant outdoor sun exposure 
such as farm or construction workers  
●  Urban indoor workers who spend weekends or 
holidays  (or  their  childhood  and  young 
adulthood) in the sun. 
Melanoma  
Australia  has  the  highest  incidence  and  mortality 
rates  for  melanoma,  as  summarised  in  Table  5 
demonstrating international trends [15]. The evidence of 
a  causative  link  with  sunlight  exposure  is  compelling, 
with severe episodic sunburn in early life correlating best 
with  melanoma  risk  [15 19].  The  Sydney  Melanoma 
Unit (SMU) has been the global pioneer in the diagnosis, 
staging  and  management  of  this  malignancy  [20 22], 
especially  with  regard  to  multi disciplinary  care  [20], 
and its contribution to the formulation of comprehensive 
clinical  practice  guidelines  published  by  the  National 
Health and Medical Research Council (NHMRC) [18]. 
The SMU has been particularly instrumental in defining 
the role and technique of sentinel lymph node mapping 
in  melanoma  [21,23]  and  has  led  international 
collaborative  clinical  and  translational  research  trials 
[24].  
Lung cancer 
Although  lung  cancer  is  only  the  third  highest 
cancer in terms of incidence, it is the leading cause of 
cancer death in males and females, as well as the top 
cause of ‘Person Years of Life Lost’ due to cancer in 
Australia.  More  than  8,000  Australians  are  diagnosed 
with  lung  cancer  each  year,  with  about  7,000  deaths 
secondary to the disease each year. One in 30 Australians 
will develop lung cancer by age 75 [1]. Relative survival 
following a diagnosis of lung cancer in the Australian 
states  during  the  1980s  and  1990s  (for  which  data  is 
available) varied in the ranges of 10.1 11.1% in males 
and 12.3% 13.7% in females at five years. More recent 
Australian data for the period 1992 97 show a five year 
relative survival of 11% for males and 14% for females. 
Comparative  international  trends  in  lung  cancer  are 
outlined in Table 6. Lung cancer incidence is decreasing 
in  males  but  increasing  in  females,  with  cigarette 
smoking the major cause in up to 90% of cases. In 2003, 
there were an estimated 10,378 new cases of all cancers 
and 7,727 deaths from all cancers in Australia attributed 
to smoking (see below) [1]. Other causes of lung cancer 
include environmental (passive) smoking (although the 
risk  is  less  than  active  smoking),  and  occupational 
exposure to asbestos.  
Management issues in lung cancer  
In  2004  the  NHMRC  published  clinical  practice 
guidelines for the prevention, diagnosis and management 
of  lung  cancer  [25].  The  primary  reason  for  the 
publication of these guidelines was to assist in educating 
and improving the practice and quality of care provided 
by  practitioners  who  manage  lung  cancer  patients  in 
Australia. The overall aim of the guidelines was thus to 
improve consistency of care and patient outcomes. These 
guidelines underscore the value and importance of multi 
disciplinary  care,  as  have  publications  from  other 
Australian centres [26,27]. To date, no national screening 
program  for  lung  cancer  exists  in  Australia,  based  on 
lack of high level evidence to support its implementation 
and  use  [25].  The  NHMRC  guidelines  contain 
comprehensive  evidence based  recommendations 
regarding the management of both non small cell lung 
cancer and small cell lung cancer by stage [25]. Despite 
the  publication  and  dissemination  of  these  guidelines, 
however, there is ongoing evidence of practice variation 
across  Australia.  For  example,  in  a  survey  of  24 
radiotherapy departments across the country, there was 
considerable variation in radiotherapy prescription doses 
for both radical and palliative treatments, immobilisation 
techniques, and CT planning based protocols [28]. Data 
such as this demonstrate the ongoing need for continued 
assessment of guideline implementation and also updates 
as new evidence becomes available.  
Smoking 
Cigarette  smoking  remains  the  largest  single 
preventable  cause  of  death  and  disease  including  lung 
cancer.  Consequently,  tobacco  control  measures, 
including  taxation  and  price  policies,  advertising 
restrictions,  public  information,  health  promotion  and 
smoking  cessation  support,  are  pivotal  in  reducing  the 
burden of disease from smoking. In 2004 the Ministerial 
Council on Drug Strategy [29] endorsed an action plan 
under  the  National  Drug  Strategic  Framework,  The 
National Tobacco Strategy (NTS), 2004-2009 [30]. The 
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Table 5  Melanoma statistics in four countries [1,4,5,79,80] 
 
Age-standardised 
incidence 
(100,000/year) 
Age-standardised 
mortality 
(100,000/year) 
Lifetime risk 
(incidence) 
Incidence trend 
over 10 years 
Mortality 
trend over 
10 years 
Most common 
cancers 
(ranking) 
Australia (2001) [1] 
Men  41 4 (world)  5 1 (world)  1 in 25  22% increase  2% increase 
(1991–2001) 
4th 
Women  31 1 (world)  2 6 (world)  1 in 35  12% increase  0% increase 
(1991–2001) 
3rd 
USA (2001) [4,5] 
Men  21 4 (world)  3 9 (world)  1 in 53  31% increase  0% increase 
(1991–2001) 
5th 
Women  13 8 (world)  1 8 (world)  1 in 78  25% increase  1% decrease 
(1991–2001) 
7th 
The Netherlands (1998) [79] 
Men  11 5 (Europe)  3 1 (Europe)  ..  21% increase  24% increase 
(1989–98) 
.. 
Women  14 8 (Europe)  2 1 (Europe)  ..  11% increase  5% increase 
(1989–98) 
.. 
UK (2000) [80] 
Men  9 7 (world)  2 7 (world)  1 in 147  59% increase  20% increase 
(1991–2001) 
12th 
Women  11 2 (world)  1 9 (world)  1 in 117  41% increase  3% increase 
(1991–2001) 
7th 
 
 
 
Table 6  Five year relative survival from lung cancer – international comparisons [3, 48, 81 84]. 
      Years after Diagnosis 
Males  Time period  Age Group  1 yr 
(%) 
2 yr 
(%) 
3 yr 
(%) 
4 yr 
(%) 
5 yr 
(%) 
Australia  1992 97  All  34.6           11.0 
New South Wales  1980 94  15 89  34.0  18.0  13.4  11.2  10.1 
Europe  1985 89  15+  32.0     12.0  1.0  10.0 
United States (SEER)  1991  All  38.9  21.9  17.0  14.0  12.4 
Females  Time period  Age Group  1 yr  2 yr  3 yr  4 yr  5 yr 
Australia  1992 97  All  37.6           14.0 
New South Wales  1980 94  15 89  37.3  20.8  15.9  13.5  12.3 
Europe  1985 89  15+  29.0     13.0     11.0 
United States (SEER)  1991  All  44.9  27.0  21.4  18.8  16.4 
Notes: 
(a)   When comparing survival and mortality data it should be noted that the denominator for survival is the population of 
patients with disease, whereas the denominator for the mortality rate from lung cancer is the whole population. Thus, 
the mortality rate may be low is there are a small number of cases with the disease, whereas poor survival results from 
patients with the disease dying relatively quickly. 
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Australian  government  reiterated  its  determination  to 
reduce  tobacco  use  by  ratifying  the  World  Health 
Organization’s  Framework  Convention  on  Tobacco 
Control [31].  
Colorectal cancer 
Colorectal  cancer  (CRC)  is  the  second  most 
common cause of death from cancer, after lung cancer. 
There are about 11,300 new cases and 4,600 deaths from 
bowel cancer each year in Australia. The lifetime risk of 
developing  bowel  cancer  is  approximately  1  in  18 
Australian men, and 1 in 26 women [1]. Risk factors for 
the  development  of  CRC  include  increasing  age,  low 
fibre diet, history of polyps and /or colitis, and family 
history of colorectal cancer.  
Population based  bowel  screening  was  tested  in  a 
national  Pilot  Program  from  November  2002  to  June 
2004.  The  National  Bowel  Cancer  Screening  Program 
[32]  commenced  a  phased  implementation  in  August 
2006.  Initially,  screening  will  be  offered  to  those 
involved in the Pilot Program and Australians turning 55 
or  65  years  of  age  between  May 1, 2006  and 
June 30, 2008.  Eligible  participants  will  receive  an 
invitation to complete a faecal occult blood test (FOBT). 
Those returning a positive FOBT result will be advised 
to  discuss  it  with  their  family  practitioner,  who  will 
generally  refer  them  for  further  investigations,  which 
will usually be a colonoscopy. 
Management issues in colorectal cancer 
In 1999, NHMRC released the ‘Guidelines for the 
Prevention,  Early  Detection  and  Management  of 
Colorectal  Cancer’  [33],  with  the  second  edition 
released  in  2005  [34].  The  guidelines  are  intended  to 
provide  a  resource  for  all  medical  practitioners  and 
health workers who require sound information directed 
toward  the  management  of  patients  with  colorectal 
cancer. These guidelines are wide ranging in scope and 
provide  information  which  covers  prevention  and 
screening, diagnosis and psychosocial matters, as well as 
the  clinical  aspects  of  surgery,  radiotherapy  and 
chemotherapy. These guidelines have been well adopted, 
used  with  demonstrated  concordance  and  implemented 
into clinical practice [35]. Another significant change in 
the management paradigm in CRC has been the patterns 
of follow up care. In the past, intensive follow up after 
treatment was not as strongly promoted. However, it has 
now been shown that intensive follow up leads to earlier 
detection  of  recurrence.  A  Cochrane  Review 
demonstrated that it also improves survival [36].  
Breast cancer 
Breast cancer is the highest cause of cancer related 
deaths among Australian women. The age standardised 
incidence of breast cancer in females has increased from 
80 per 100,000 population in 1983 to 117 per 100,000 
population  in  2002.  It  is  projected  that  there  will  be 
13,261  new  cases  in  2006  and  14,800  in  2011  in 
Australia. The lifetime risk of developing breast cancer is 
approximately 1 in 11 women in Australia. In 2002 there 
were  approximately  114,000  women  alive  with  a  past 
diagnosis of breast cancer [37]. There are various risk 
factors  related  to  the  development  of  this  malignancy, 
including  increasing  age,  hormonal  factors,  nulliparity, 
exogenous oestrogen, a positive family history in first 
degree relatives, and previous history of breast cancer or 
benign breast disease [38]. 
Management issues in breast cancer  
The  National  Breast  and  Ovarian  Cancer  Centre 
(NBOCC) [39] is Australia’s main body for breast and 
ovarian cancer control, originally established in 1995 by 
the Australian government. The NBOCC has produced a 
spectrum  of  publications  and  resources  including 
comprehensive  evidence based  clinical  practice 
guidelines relating to all aspects of breast cancer and its 
management. These aspects include screening and early 
detection,  the  management  of  early,  advanced,  and 
metastatic  breast  cancer  [38],  radiotherapy  and  breast 
cancer, the psychosocial care of adults with cancer, and 
multi disciplinary cancer care [39]. 
The  BreastScreen  Australia  public  mammography 
screening program [40] commenced in most Australian 
states  in  1991.  Increased  cancer  incidence  rates  were 
seen in the targeted age groups between 50 and 69, and 
were greatest in the 60 64 age group. The incidence rates 
increased from 216 per 100,000 population in 1992 to 
334 per 00,000 population in 2002. Table 7 demonstrates 
a  global  ranking  of  incidence  and  mortality  for  breast 
cancer in females with data from selected countries [3, 
41].  
Prostate cancer 
In  Australia,  prostate  cancer  is  the  second  most 
common  type  of  cancer  in  men  (after  skin  cancer). 
Relatively little is known about the aetiology of prostate 
cancer in some men. It is a disease of older men, being 
rare  under  the  age  of  50.  When  it  does  occur  in  men 
under 50, it is more likely in a man with a family history 
of  prostate  cancer.  Australians  may  be  more  prone  to 
develop  prostate  cancer  as  it  has  been  found  to  be 
associated with certain diets – including those high in 
animal  fats,  low  in  plant  food,  and  possibly  low  in 
certain elements, antioxidants and vitamins – as well as 
occupational  exposure  to  certain  substances,  including 
cadmium and rubber [42]. 
While  variations  on  the  risk  strata  exist,  for  the 
purpose  of  this  review,  the  American  Urological 
Association (AUA) scheme is referenced, as follows [43]: 
●  Low  risk:  PSA≤  10ng/ml,  Gleason  score  ≤  6 
and clinical stage T1C or T2a 
●  Intermediate risk: PSA> 10ng/ml to 20ng/ml or 
a Gleason score of 7 or clinical stage T2b 
●  High risk: PSA>20 ng/ml or a Gleason score of 
8 to 10 or clinical stage ≥T2c  
7 
 ES Koh et al. Biomed Imaging Interv J 2008; 4(3):e30     
    This page number is not 
    for citation purposes 
Table 7  Global  ranking  of  incidence  and  mortality  for  breast  cancer  in  females,  selected  countries,  2002 
GLOBOCAN.  (Rates  expressed  per  100,000  populations  and  age standardised  to  the  year  2002 
Standard Population of country and to World Standard Population (ASR (W)) [3]. 
  Incidence  Mortality 
Population (Female)  Numbers  Crude  ASR (W)  Numbers  Crude  ASR (W) 
World  1,151,298  37.4  37.4  410,712  13.3  13.2 
More Developed Countries  636,128  103.7  67.8  189,765  30.9  18.1 
Less Developed Countries  514,072  20.9  23.8  220,648  9.0  10.3 
Australia  11,176  114.1  83.2  2,667  27.2  18.4 
Canada  19,540  124.0  84.3  5,305  33.7  21.1 
New Zealand  2,330  120.0  91.9  670  34.5  24.5 
United Kingdom  40,298  135.5  87.2  13,303  44.0  24.3 
United States of America  209,995  143.8  101.1  42,913  29.4  19.0 
Central and Eastern Europe  100,262  63.4  42.6  45,310  26.7  17.9 
Northern Europe  62,425  128.8  82.5  19,789  40.8  22.6 
South Eastern Asia  58,495  21.8  25.5  26,818  10.0  11.8 
Southern Europe  72,458  97.8  62.4  24,617  33.2  18.1 
Western Europe  125,604  134.3  84.5  39,297  42.0  22.3 
Notes: 
1.  Cancer numbers and rates are estimates for the middle of 2002, from the most recent data available, generally 3 5 years 
earlier. 
2.  Rates are expressed per 100,000 populations and age standardised to the year 2002 Standard Population of the 
corresponding country and to the World Standard Population (ASR (W)). 
3.  The Age Standardized Rate (ASR, world standard) is calculated using the 5 age groups 0 14,15 44,45 54,55 64,65+ 
years. 
 
 
 
Table 8  Breast cancer in females: age standardised rate and five year relative survival proportions by region and 
socioeconomic status, Queensland, 1996 2002. [45]. 
Characteristic 
Incidence 
(Average number of  
cases per year) 
ASR  
(Age-Standardized Rate) 
Five-year  
relative survival  
(%) 
Geographic area 
Major city  1,087  119.5  86.6 
Inner regional  575  120.3  87.0 
Outer regional  280  99.9  85.8 
Remote  33  89.5  81.9 
Socio-economic status (SES) 
Affluent  143  129.4  88.1 
Middle 80% SES  1,716  115.5  86.5 
Disadvantaged  115  106.2  84.7 
Source: Geographical differentials in cancer incidence and survival in Queensland, 1996 to 2002 [45]. 
Notes: 
(a)  ASR is the Age Standardized Rate 
(b)  Relative survival compares the survival of persons diagnosed with cancer 
  (observed) with that experienced by the same age  and sex matched population to which they belong (expected). The 
ratio of observed to expected is used to estimate the proportion of people whose risk of dying has been affected by the 
disease. This method of analysis does not require knowledge of the cause of death. 
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Management issues in prostate cancer 
The National Health and Medical Research Council 
(NHMRC) is Australia's main body for supporting health 
and medical research, and for developing health advice 
for the Australian community, health professionals and 
governments.  In  2002,  the  NHMRC  released  the 
“Clinical practice guideline: Evidence based information 
and recommendations for the management of localised 
prostate  cancer”  [42].  Publication  of  these  evidence 
based  guidelines  has  been  particularly  important  in 
outlining management options and controversies, when 
weighing  up  potential  treatment related  benefits  with 
relevant morbidities.  
Localized low- to intermediate- risk prostate cancer 
Options  for  the  management  of  localised  prostate 
cancer  include  radical  prostatectomy,  radiotherapy  and 
active surveillance. Radiotherapy includes external beam 
and interstitial radiotherapy (brachytherapy) treatments. 
These  interventions  are  options  for  the  treatment  of 
localised  prostate  cancer  because  the  data  currently 
available  in  the  literature  does  not  provide  sufficient 
clear cut  evidence  to  indicate  the  unquestioned 
superiority of any one form of treatment [42]. 
Localised high-risk prostate cancer 
Although  active  surveillance,  non nerve  sparing 
prostatectomy,  high dose  rate  brachytherapy  and  high 
dose external beam radiotherapy remain options for the 
management of patients with high risk localised disease, 
recurrence  rates  are  also  high.  Based  on  results  of 
randomised controlled trials, the use of hormone therapy 
in  combination  with  conventional  radiotherapy  may 
prolong survival [43]. 
Hormone-refractory prostate cancer  
Although  hormonal  manipulations,  such  as 
luteinising hormone releasing hormone (LHRH) agonists 
or castration, are initially effective for 90% of prostate 
cancer patients, all eventually progress after a median of 
18 24  months  of  treatment  to  become  “androgen 
independent”  (or  hormone refractory).  Upon 
progression, secondary hormonal manipulations are often 
employed; however, these treatments are generally less 
effective, and any anti cancer effects are usually short 
lived.  The  intravenous  chemotherapy  agent  Docetaxel 
has  been  used  in  the  treatment  of  HRPC  and 
demonstrated a survival benefit in selected patients [44]. 
INEQUALITIES IN CANCER SUSCEPTIBILITY AND 
HEALTH OUTCOMES  
Despite  the  fact  that  Australia  ranks  among  the 
countries  with  the  lowest  mortality  rates  overall,  there 
are  defined  sub groups  of  the  population  with 
documented  inferior  outcomes,  particularly  women 
residing in more regional and remote geographic areas 
(see later section on access issues) [45], those of lower 
socioeconomic  status  [41]  (see  Table  8),  and  those  of 
indigenous backgrounds [46,47].  
Indigenous Australians 
Indigenous Australians who do not live in the cities 
are particularly disadvantaged in accessing radiotherapy. 
Their strong links to place, family and culture mean that 
travelling  to  urban  centres  for  radiotherapy  is  a 
significant  problem.  The  greater  differences  in  death 
rates, compared to incidence rates, between indigenous 
and  non indigenous  people  could  reflect  a  higher 
proportion  among  indigenous  people  of  cancers  with 
high case fatality rates, a generally more advanced stage 
of cancer at time of diagnosis, or differences in treatment 
outcomes by stage of cancer at diagnosis [48]. In a study 
of 815 indigenous and 810 non indigenous people living 
in  Queensland  and  diagnosed  with  cancer  from  1997 
2002,  the  likelihood  of  death  from  cancer  was  30% 
higher  for  indigenous  cases  than  for  non indigenous 
cases  after  accounting  for  cancer  stage  at  diagnosis, 
treatment, and the higher rates of co morbidities (such as 
diabetes,  chronic  renal  disease,  respiratory  disease  and 
acute  coronary  conditions)  existing  among  indigenous 
cases [49]. Analyses of cancer and cancer services for 
Indigenous  people  in  the  Northern  Territory  have 
highlighted  the  fact  that  the  absolute  differences  in 
survival  after  diagnosis  with  cancer  are  greatest  for 
cancers  with  the  highest  survival  in  non indigenous 
people  [46].  A  2004  review  concluded  that  ”the 
experience  of  indigenous  people  and  cancer  provides 
evidence  that  the  Australian  health  system  is  not 
operating  as  effectively  for  indigenous  people  as  for 
other  Australians”  and  that  there  was  a  need  for 
“strengthening  primary  healthcare  services,  reducing 
barriers for access to specialist services and improving 
collaboration between the two” [46].  
Geographic differences 
There  is  increasing  evidence  to  suggest  that  more 
than  half  a  million  Australians  who  live  outside  state 
capital  cities  [50]  are  at  risk  of  significantly  poorer 
survival  outcomes  following  a  cancer  diagnosis,  than 
people  with  similar  diagnoses  who  reside  in  major 
metropolitan  areas  [51].  People  with  cancer  living  in 
remote and rural areas are diagnosed at a later stage than 
their  city  counterparts  [52],  and  moreover,  are  more 
likely  to  die  from  cancers  such  as  lung,  cervix,  and 
uterine  malignancies  the  further  they  are  located  from 
city centres [53]. Specific indicators of reduced access to 
cancer  care  services  in  remote  and  rural  areas  include 
poorer  state of the art  diagnostic  tests,  staging  and 
treatment of prostate cancer [54], less breast conserving 
surgery  [55],  and  lower  probability  of  completing 
external beam radiotherapy when referred for treatment 
of  rectal  cancer  [56].  As  recently  as  2004,  there  was 
ongoing  published  evidence  in  the  Medical  Journal 
Australia demonstrating that people with cancer residing 
in regional New South Wales were 35% more likely to 
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die within five years of diagnosis than patients residing 
in  urban  centres  [52].  Mortality  rates  increased  with 
remoteness to cancer facility.  
Geographic differences and socio-economic status (SES) 
In  2006  the  AIHW  published  a  comprehensive 
overview  report  [41]  addressing  epidemiologic  aspects 
and clinical outcomes in breast cancer in Australia. The 
most recent data linking geographic differences and SES 
come from the state of Queensland (see Table 8). ‘Major 
city’  and  ‘inner  regional’  areas  had  higher  five year 
survival  rates  with  86.6%  and  87.0%  survival 
respectively,  compared  with  ‘Outer  regional’  and 
‘Remote’  areas  with  five year  survival  rates  of  85.8% 
and  81.9%  survival,  respectively,  in  the  1996 2002 
period.  Over  this  same  period,  ‘Affluent’  areas  of 
Queensland had the highest five year survival rates with 
88.1% compared to ‘Middle 80% SES’ areas with 86.5% 
survival and the ‘Disadvantaged’ areas with 84.7% five 
year relative survival [41]. 
ADEQUACY OF FACILITIES AND SERVICES BASED ON 
THE IDEAL PHILOSOPHY OF CANCER CARE  
This  section  will  address  cancer  services  by 
specialty type – surgical, medical and radiation oncology, 
and palliative care services. 
Surgical oncology services  
Surgical expertise tends to be focused on anatomical 
sites  rather  than  types  of  pathology.  Consequently, 
individual  surgical  specialists  treat  varying  proportions 
of neoplastic and non neoplastic conditions. A national 
report is currently being prepared with respect to surgical 
oncology  services,  by  linking  data  from  Medicare  on 
MBS claims for surgical procedures identified as being 
primarily  cancer related  and  also  documenting  the 
geographic distribution of these claims.  
Complexity of a surgical oncology intervention, volume 
of procedures and outcome 
There is increasing evidence that outcome of cancer 
care, particularly for complex difficult primary surgery, 
is  linked  to  the  volume  of  interventions  (for  example, 
operations) undertaken. In Australia there is, for example, 
evidence  showing  volume outcome  benefits  for 
individual colorectal surgeons when undertaking difficult 
rectal surgery, though this difference is not apparent for 
less difficult surgery [34].  
Medical oncology services  
The  estimated  number  of  medical  oncologists  per 
new  case  of  cancer  in  2007  varied  considerably,  with 
most states and territories (except Victoria) experiencing 
an apparent shortfall. The Australian Medical Workforce 
Advisory Committee (AMWAC) reported that, in 2001, 
there  were  14  medical  oncologists  and  haematological 
oncologists  per  million  population  in  Australia. 
AMWAC recommended that this number be increased to 
16 per million population, but did not identify the ratio 
for each specialty separately [57].  
Availability of chemotherapy drug agents 
Cancer  treatment  accounts  for  6%  of  the  health 
expenditure. Even drug costs, about which much is heard, 
are quite modest. The cost of anti cancer drugs is only 
15% of the most expensive drug group (lipid lowering 
agents)  and  2.7%  of  the  total  expenditure  on  the 
Pharmaceutical Benefit Scheme (PBS) [6]. Indirect costs, 
that  is,  costs  other  than  the  healthcare  costs,  are 
unmeasured and often ignored. For a devastating disease 
like  cancer,  these  are  generally  much  greater  than  the 
cost of treatment [58].  
Chemotherapy  is  mostly  delivered  by  intravenous 
administration. It is provided in a variety of hospital, as 
well  as  public   and  private sector  outpatient  settings 
throughout Australia, including many rural locations. In 
most settings, chemotherapy regimens are determined by 
medical oncologists but are administered by nursing staff, 
under the supervision of either a medical oncologist or an 
appropriately qualified physician.  
In 2006, more than 300,000 Medicare claims were 
made  for  chemotherapy  administration  throughout 
Australia. The number of claims per new case of cancer 
varied greatly among the states and territories. The PBS 
Schedule  is  part  of  the  wider  Pharmaceutical  Benefits 
Scheme [34] managed by the Department of Health and 
Ageing and administered by Medicare Australia, which 
provides  medicines  to  be  dispensed  to  patients  at  a 
government subsidised  price.  To  explore  usage  of 
chemotherapeutic  agents,  we  examined  data  on  PBS 
services for two selected high cost drugs, both relatively 
new agents approved for defined indications on the basis 
of evidence from randomised controlled trials [59, 60]. 
1.  Trastuzumab, a monoclonal antibody treatment 
indicated  in  the  management  of  HER2 neu 
positive breast cancer;  
2.  Docetaxel, an agent indicated for the adjuvant 
treatment  of  node positive  breast  cancer  in 
combination  with  an  anthracycline,  for  the 
treatment  of  locally  advanced  or  metastatic 
breast  cancer  as  second line  chemotherapy, 
metastatic  hormone refractory  prostate  cancer 
[60], advanced, metastatic ovarian cancer, and 
second line  therapy  in  locally  advanced  or 
metastatic non small cell lung cancer.  
The  Federal  Government  accepted  a 
recommendation  from  the  Pharmaceutical  Benefits 
Advisory committee (PBAC) to list Trastuzumab on the 
PBS, as of October 1, 2006, for a maximum period of 12 
months. Of the 14,000 women who are diagnosed with 
breast  cancer  annually  in  Australia,  around  2100  are 
expected to be treated with Trastuzumab per year. The 
calculated  costs  of  the  52  weeks  of  treatment  was 
estimated  to  be  in  the  order  of  $50,000  per  eligible 
patient,  with  the  listing  of  Trastuzumab  anticipated  to 
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add $470 million to the PBS expenditure between 2006 7 
and 2009 2010 [61] .  
Similarly, with respect to Docetaxel, extension of its 
use in the setting of HRPC was initially rejected by the 
PBAC  in  July  2005  because  of  uncertain  and 
unacceptable  cost effectiveness.  In  a  re submission  in 
November  2006,  its  use  was  approved  in  HRPC.  On 
updated economic evaluation, its cost was estimated to 
be  in  the  range  of  $15,000 $45,000  (intention to treat 
population). The likely number of patients was estimated 
to be less than 10,000 in Year 4. The financial cost/year 
to the PBS was estimated to be in the range of $30 60 
million in Year 4 [62]. 
Radiation oncology services 
There  is  a  significant  deficit  in  radiotherapy 
resources  in  Australia,  both  in  staffing  (radiation 
oncologists, medical physicists, and radiation therapists) 
and in equipment. Waiting lists are an obvious outcome 
measure of the resource shortage, and long waiting time 
for various cancers have been documented in Australia. 
Evidence  for  this  exists  in  clinical  settings  for  some 
tumour  sites,  such  as  post operative  head  and  neck 
cancer,  small  cell  lung  cancer,  high  grade  cerebral 
gliomas  [63]  and  cervix  cancer  (64),  where  tumour 
control may be adversely affected [65]. In 2001 and 2002, 
the  Royal  Australian  and  New  Zealand  College  of 
Radiologists  performed  audits  to  specifically  address 
waiting  times  for  radiotherapy  in  Australia  [66].  The 
results show a steady decline in the number of patients 
commencing  treatment  in  a  timely  fashion,  with 
approximately  40%  of  patients  receiving  curative 
treatment, 30% receiving palliative treatment, and 56% 
receiving  emergency  treatment  starting  outside  of 
standard  good  practice  times.  The  Collaboration  for 
Cancer  Outcomes  Research  and  Evaluation  (CCORE) 
has reported an evidence base to support a utilisation rate 
of 52.2%, resulting in a disparity of approximately 18% 
between those cancer patients who should – and those 
who  actually  do  –  receive  radiation  treatment  [67].  In 
2002, this represented approximately 15,000 patients in 
Australia  who  could  have  potentially  benefited  from 
treatment,  but  were  unable  to  access  radiotherapy 
services. 
LIMITATIONS OF CURRENT CANCER CARE PRACTICE IN 
AUSTRALIA 
Optimizing  Cancer  Care  in  Australia  is  a 
consultative  report  prepared  in  2003  by  the  Clinical 
Oncological  Society  of  Australia,  The  Cancer  Council 
Australia  and  the  National  Cancer  Control  Initiative, 
outlining  key  reforms  required  to  ensure  optimal 
treatment for cancer patients [2]. It identifies three key 
areas  where  the  “health  system”  has  failed  to  provide 
optimal  care  for  cancer  patients.  These  key  areas  are: 
models  of  cancer  care,  quality  of  cancer  care,  and 
resource issues in cancer care. 
Models of cancer care 
Traditional versus integrated multidisciplinary care 
(IMDC) 
Medicare  and  the  private  health  insurance  system 
cater for the traditional model of care where the general 
practitioner (GP) refers a patient to a specialist (usually a 
surgeon) who conducts the primary intervention, usually 
the  removal  of  a  tumour.  Patients  may  then  see  other 
cancer  specialists  sequentially  for  opinions  before  (but 
more  often  after)  the  primary  intervention.  This 
traditional model is criticised for its dependence upon the 
primary  specialist  reaching  a  conclusion  that  further 
referral is necessary. They perceive too great a risk of 
suboptimal  therapy  unless  there  is  a  more  formalised 
method of accessing ‘integrated multidisciplinary care’ 
(IMDC).  Much  work  has  been  invested  in  developing 
and implementing this concept and model of care. This 
work  has  been  summarised  in  reports  issued  by  the 
National  Breast  and  Ovarian  Cancer  Centre  [39],  and 
includes the management of colorectal cancer [33, 34], 
breast [38, 39], lung [25, 26]and other malignancies such 
as melanoma [18].  
Quality of cancer care 
Improving quality of cancer care 
Several major initiatives are underway in Australia 
which seek to assess mechanisms to improve quality in 
cancer  care.  What  is  striking  about  these  initiatives  is 
that there are relatively so few of them, especially for 
cancers other than breast cancer. Other drivers for quality 
could  include  the  Medicare  Benefits  Schedule  (MBS) 
[68].  The  schedule  may  need  to  change  to  promote 
quality  care.  Consideration  needs  to  be  given  to 
reviewing  the  MBS  items  with  a  view  to  promoting 
higher quality cancer care [69]. 
Improving quality through information and research 
There are many gaps in our knowledge of the cancer 
care  process,  such  as  how  advanced  the  disease  is  at 
diagnosis,  how  people  are  treated,  as  well  as  how 
treatment and potential complications affect their quality 
of life. Researching these issues is vital to our ability to 
provide optimal care. Funding for this type of research is 
relatively limited, but it is needed to engage in a dialogue 
between cancer clinicians and healthcare policy makers 
to help ensure services are both meeting the needs and 
are cost effective.  
Quality of healthcare providers 
●  Lack  of  standards  in  training  curricula  and  a 
focus  on  process  instead  of  the  education 
system’s capacity to deliver positive healthcare 
outcomes.  
●  No credentialing of individual practitioners nor 
accreditation of healthcare services. 
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●  Poor working conditions, due in part to patient 
through puts based on an individual clinician’s 
willingness to meet demand rather than national 
standards  determined  by  population  need  and 
each hospital’s demonstrated capacity.  
●  Inadequate arrangement for clinical training. 
●  Unstructured career paths and lack of diversity 
in healthcare professional roles. 
Resource issues in cancer care 
Work force (shortages, roles, training, 
communication skills) 
The cancer care workforce faces shortages in almost 
every category. There are shortages of specialised cancer 
nurses,  radiation  therapists,  medical  physicists, 
pharmacists and all cancer specialist clinicians (surgical 
oncologists,  medical  oncologists  and  radiation 
oncologists).  The  shortages  show  themselves  most 
acutely in the regional areas outside major capital cities. 
General practice also requires development, as cancer is 
increasingly  being  treated  in  the  community. 
Communication  is  widely  recognised  as  problematic, 
especially as Australia has a culturally and linguistically 
diverse background. 
Access issues 
An unprecedented increase in cancer incidence and 
prevalence  has  lead  to  marked  disparities  in  cancer 
mortality  and  morbidity  across  population  groups  (eg 
poorer  outcomes  for  indigenous,  rural  and  remote 
communities) as discussed earlier. This is acutely shown 
in access to cancer care in rural and regional centres. 
A number of key access issues affect the quality of 
cancer care. 
(1) Access to radiotherapy units 
Radiation oncology is in a period of unprecedented 
change due to increases in the complexity of treatment 
and improvements in the diagnosis and staging of cancer. 
Such  changes  include  the  expanding  use  of  Magnetic 
Resonance  Imaging  (MRI),  Ultrasonography,  Positron 
Emission  Tomography  (PET)  and  Single  Photon 
Emission  Computed  Tomography  (SPECT)  scanning, 
and the need for image fusion, multi leaf collimators and 
conformal therapy, 3D planning, and intensity modulated 
radiotherapy  (IMRT)  –  all  of  which  will  increase  the 
demands for improved patient immobilisation [70]. The 
delay  in  funding  for  new  technologies,  due  to 
government  bodies  waiting  for  evidence based  data  to 
show  an  improved  outcome,  thus  creates  significant 
delays in implementation especially for radiotherapy. In 
the  context  of  radiation  oncology  practice,  creditable 
results may require many years of follow up. 
The Royal Australian and New Zealand College of 
Radiologists (RANZCR) routinely surveys waiting times. 
In May 2001, 44% of patients surveyed started treatment 
within  the  optimum  waiting  time,  30%  were  within 
acceptable times, and 26% were outside the acceptable 
range [66]. Australian Council on Healthcare Standards 
data show that the proportion waiting more than three 
weeks for radiotherapy has doubled between 1999 and 
2001 to 20% of people. The National Strategic Plan for 
Radiation  Oncology  (Australia)  identified  a  lack  of 
access  to  radiotherapy  treatment  centres,  creating 
considerably real and present hardship for many patients 
[71]. 
(2) Access to pharmaceuticals (drugs) 
As outlined earlier, cancer drugs that are difficult to 
access fall into three categories: new drugs that are not 
yet approved either by Pharmaceutical Benefits Advisory 
Committee  or  the  Therapeutic  Goods  Administration 
(TGA) for that indication; older drugs that have not been 
approved for the use that they are being applied to; or 
older drugs that are no longer on the Australian Register 
of Therapeutic Goods. 
(3) Access to services including palliative care 
Travelling to a treatment centre is a serious barrier 
to  access.  Substantial  cost  is  incurred  in  accessing 
treatment and some people cannot afford it, especially 
for prolonged periods of radiotherapy. Greater access to 
home care, better access to psychological support, and 
support  for  carers  and  families  can  all  decrease  the 
impact of cancer. Although overall access to palliative 
care in Australia is adequate, referral to palliative care 
units is often too late or only during a crisis, and one 
third  of  the  potential  population  is  never  referred  [2]. 
One common problem is late referral, which is closely 
related  to  the  failure  to  involve  palliative  care 
practitioners in care planning at an earlier stage. Part of 
the  solution  is  to  educate  specialists,  GPs  and  the 
community about palliative care and to change its image. 
This is particularly pertinent for special groups such as 
Australian  Aboriginals  and  those  from  non English 
speaking backgrounds, ensuring that they know about the 
services and how to access it. 
POTENTIAL SOLUTIONS AND FUTURE IMPROVEMENTS IN 
CANCER CARE AND SERVICE DELIVERY 
In the 2004 5 Federal budget, almost $190 million 
in funding was pledged to be made available over a five 
year period until 2008 9 for the ‘Strengthening Cancer 
Care’  initiative.  Most  of  the  states  and  territories  in 
Australia  have  now  developed  their  own  local  cancer 
control plans. In particular, the two most populous states, 
Victoria and New South Wales, have produced a ‘Cancer 
Services  Framework  for  Victoria’  [72]  and  the  NSW 
Cancer  Plan  2004 2006,  respectively  [73].  This  plan 
outlined  33  specific  goals  in  the  10  strategic  areas, 
covering:  
●  Coordination of cancer control 
●  Cancer prevention and early detection 
●  Cancer service provision – the patient’s journey 
●  Special issues in cancer care 
●  Cancer information 
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●  Cancer education 
●  Cancer workforce 
●  Cancer research 
●  Cancer fundraising  
●  Quality, evaluation and accreditation 
The  strengths  of  these  successive  comprehensive 
national  and  state based  initiatives  and  reports,  have 
been to identify priority cancers and strategies that have 
the  potential  to  improve  cancer  outcomes,  decrease 
morbidity  and  mortality  and  address  inequalities  in 
cancer care [2]. However there are several major areas of 
weaknesses  in  these  initiatives.  These  relate  to  the 
relative  lack  of  implementation  plans,  the  absence  of 
dedicated funding for implementation, too few economic 
analyses supporting priority actions and strategies, and 
little or no evaluation of the uptake or impact of cancer 
control plans [74]. These challenges are magnified by the 
fact that those responsible for producing these plans are 
not always the same groups who have the authority to 
execute  and  implement  them,  and  who  may  have 
differing  priorities.  For  example,  the  Cancer  Institute 
NSW has control over a very small part of NSW’s health 
expenditure on cancer. This is in contrast, notably, with 
the British National Health Service, which has both the 
authority to both produce strategic plans and implement 
them [74]. Other weaknesses include the lack of well 
structured  implementation  strategies  and  a  clear 
assignment  of  responsibility  and  accountability 
mechanisms.  
As outlined in the COSA report [75], cancer care in 
Australia is thus compounded by associated population 
pressures,  and  faces  the  following  demographic 
challenges and systemic problems: 
●  Fragmentation  of  the  system  across  multiple 
tiers,  compromising  efficiency  of  training, 
planning, recruitment and retention processes. 
●  Established priorities based on requirements of 
disparate  organisations  rather  than  on 
Australia’s national healthcare needs as shown 
by epidemiological data.  
●  Bureaucratisation  and  politicisation  of 
government funded health services. 
●  No  national  framework  to  facilitate  staff 
movement or re entry across the system. 
●  No infrastructure for ushering in, and adapting, 
to rapid technological change.  
●  No  national,  independent  approach  to  data 
collection and use.  
Optimising Cancer Care 
The Optimising Cancer Care in Australia (OCCA) 
report proposed 12 key recommendations and 19 actions 
items. These related to the key areas of change: models 
of cancer care, quality of cancer care, resources issues in 
care and improving the delivery of cancer care [2]. The 
recommendations  emphasised  integrated 
multidisciplinary  care,  care  throughout  the  cancer 
journey,  including  palliative  and  supportive  care,  and 
improved  consumer  access  to  information.  There  were 
also  recommendations  for  the  development  of  an 
accreditation  system  for  cancer  services,  improved 
access to clinical trials, psycho oncology services and to 
new  and  accepted  drugs,  implementation  of  already 
existing workforce plans for the oncology workforce and 
for radiation oncology, revision of the system of support 
for the travel of patients and carers to receive care, and 
special  attention  to  equity  of  access,  especially  for 
indigenous  Aboriginal  people.  The  recommendations 
were intended for consideration by the Commonwealth 
Minister for Health and Ageing in concert with state and 
territory health authorities. 
Strengthening Cancer Care 
“Strengthening Cancer Care” was released prior to 
the  federal  election  in  2004  by  the  former  Coalition 
government  [76].  This  document  outlined  a  series  of 
initiatives to improve cancer care in Australia, including 
supporting  Australians  living  with  cancer  and  the 
professionals  who  care  for  them,  enhancing  screening 
and  prevention  efforts  in  bowel  and  skin  cancer, 
prevention of smoking in pregnancy, better access to Pap 
smears for cervical cancer, ensuring better coordination 
for  national  cancer  efforts,  and  more  research  funding 
dedicated to cancer and cancer care. Funding of almost 
$190 million for these cancer care initiatives in the five 
years  to  2008 2009  had  been  approved.  State  cancer 
plans now exist for each mainland state in Australia. The 
Northern Territory has recently commissioned a group to 
develop its cancer plan. These plans cover the spectrum 
of cancer control activity from prevention and screening 
to  palliation  and  rehabilitation.  They  provide  a 
framework  for  benchmarking  services  and  for 
prioritising funding initiatives.  
FUTURE VISION AND DIRECTIONS OF CANCER CARE IN 
AUSTRALIA  
Cancer outcomes in Australia are among the best in 
the  world  but  there  remains  significant  morbidity, 
mortality and expenses involved. The major issues for 
Australia are quality of service, distribution and access to 
services and the increasing cost of drugs and technology. 
Strategies  to  improve  the  quality  of  service  include 
accreditation  of  training  institutions,  credentialing  of 
practitioners  and  improvements  in  information 
technology.  Accreditation  and  credentialing  recognise 
the  contribution  of  expertise  to  better  outcomes.  The 
current  debate  surrounds  the  best  method  to  enforce 
accreditation and the content of the standards that will be 
used, such as that outlined and suggested in the ‘Cancer 
Services  Framework  for  Victoria’  report  [72]. 
Meaningful  standards  will  also  require  significantly 
better  information  management.  Currently  only 
incidence,  mortality  and  survival  data  are  routinely 
collected  and  reported.  Staging  and  treatment  data  are 
only available from a limited number of hospital based 
registries such as those in South Australia. There are also 
initiatives  to  develop  and  assess  cancer  multi 
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disciplinary  teams  with  more  objective  criteria  and 
performance benchmarks [77]. 
Australia  has  an  extremely  dispersed  geographic 
population.  One third  of  the  population  lives  outside 
major  metropolitan  centres.  Recent  initiatives  have 
sought to improve the provision of services in rural and 
regional areas with the opening of new cancer centres in 
many major country towns in Victoria and NSW. There 
is no radiotherapy service in Darwin, the capital of the 
Northern Territory, and cancer patients have to travel a 
minimum of four hours (by flight) to the nearest service. 
Providing services in isolated centres means it is more 
expensive because a minimum of two linear accelerators 
are  required  to  prevent  interruptions  to  treatment  by 
equipment  breakdowns.  Staffing  may  be  difficult 
because  of  the  overall  shortages  of  skilled  staff, 
particularly  at  a  senior  level.  Establishment  of  cancer 
networks, linking metropolitan areas with more regional 
and remote areas, in terms of staff, training, and sharing 
of other resources facilitated by appropriate information 
and communication technologies (ICT) may be one of 
the  potential  solutions  to  the  challenges  burgeoning 
cancer  care  in  an  ageing  population.  The  high  cost of 
new  biological  agents,  as  well  as  new  imaging  and 
treatment  technology  presents  a  major  challenge  to 
health  services  that  are  already  short  of  funding. 
Technological innovations such as IMRT may prolong 
treatment  duration  and  reduce  patient  throughput  and 
thus  decrease  treatment  capacity.  Technological 
innovation  is  often  introduced  without  evidence  of 
benefit and safety that would be required for new drugs.  
In summary, cancer care in Australia, as measured 
by selected outcomes, are among the best in the world; 
however  there  continues  to  be  evidence  of  health 
inequalities  especially  among  patients  residing  in 
regional and remote areas, the indigenous population and 
those  of  lower  socio economic  classes.  Ongoing 
implementation  of  the  many  national  and  state  cancer 
control plans and evaluation of their effectiveness will be 
needed to pursue the goal of optimal cancer care. 
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